Navigation
Life Science Cluster für Hamburg und Schleswig-Holstein

News

Your contact person

Manager PR & Communications Jan Phillip Denkers

Filter reset
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases (Picture: ©Topas Therapeutics)

Topas Therapeutics Extends Series B

Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today ...

Read more …
Job board